Supplementary 1: PRISMA-P checklist

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) checklist: recommended items to address in a systematic review protocol*

<table>
<thead>
<tr>
<th>Section and topic</th>
<th>Item No</th>
<th>Checklist item</th>
<th>Location in manuscript (page number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMINISTRATIVE INFORMATION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title:</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Identification</td>
<td>1a</td>
<td>Identify the report as a protocol of a systematic review</td>
<td></td>
</tr>
<tr>
<td>Update</td>
<td>1b</td>
<td>If the protocol is for an update of a previous systematic review, identify as such</td>
<td>N/A</td>
</tr>
<tr>
<td>Registration</td>
<td>2</td>
<td>If registered, provide the name of the registry (such as PROSPERO) and registration number</td>
<td>6</td>
</tr>
<tr>
<td>Authors:</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Contact</td>
<td>3a</td>
<td>Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author</td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>3b</td>
<td>Describe contributions of protocol authors and identify the guarantor of the review</td>
<td></td>
</tr>
<tr>
<td>Amendments</td>
<td>4</td>
<td>If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments</td>
<td>N/A</td>
</tr>
<tr>
<td>Support:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
| Sources | 5a | Indicate sources of financial or other support for the review | 1 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | 1 |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | 1 |

### INTRODUCTION

**Rationale**

6  
Describe the rationale for the review in the context of what is already known

**Objectives**

7  
Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)

### METHODS

**Eligibility criteria**

8  
Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review

**Information sources**

9  
Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage

**Search strategy**

10  
Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated

**Study records:**

**Data management**

11a  
Describe the mechanism(s) that will be used to manage records and data throughout the review

2
<table>
<thead>
<tr>
<th>Table 1. Methods section for systematic review of adverse events interventions in surgical patients: a modified version of the PRISMA 2015 statement for systematic reviews and meta-analysis of adverse events interventions.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Selection process</strong></td>
</tr>
<tr>
<td><strong>Data collection process</strong></td>
</tr>
<tr>
<td><strong>Data items</strong></td>
</tr>
<tr>
<td><strong>Outcomes and prioritization</strong></td>
</tr>
<tr>
<td><strong>Risk of bias in individual studies</strong></td>
</tr>
<tr>
<td><strong>Data synthesis</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Meta-bias(es)</td>
</tr>
<tr>
<td>Confidence in cumulative evidence</td>
</tr>
</tbody>
</table>

*It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.*
Supplementary 2: Draft search terms

Search terms

Virus terms
- Middle eastern respiratory syndrome
  - MERS
- Severe acute respiratory syndrome
  - SARS
- Coronavirus
- Ebola
- Marburg
- Epstein Barr virus
- Cytomegalovirus
- Varicella Zoster Virus
- Other Human Herpes Viruses
- Herpes Simplex Virus
- Influenza
- Influenza A
- Influenza B
- Influenza C
- Influenza D
- Coxsackie
- Hepatitis A
- Enterovirus
- Rhinovirus
- Parvovirus
- Ross River Virus
- Chikungunya
- Semliki Forest Complex Viruses
- West Nile River virus
- Dengue
- Yellow Fever
- Zika
- Rotavirus
- Mumps
- Measles
- Parainfluenza
- Respiratory Syncytial Virus
- Human Metapneumovirus
- Adenoviruses
- Norovirus
- Sapovirus
- Astrovirus*
- COVID

**Long-term phrases**
- Long-term
- Longterm
- Persistent
- Recurrent
- Chronic
- Post-viral
- Post-infectious
- Post infectious

**Treatment terms**
- Treatment*
- Therap*
- Intervention
## Supplementary 3: Draft data extraction table

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Setting</th>
<th>Participant characteristics</th>
<th>Name of virus</th>
<th>Outcomes</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Mean age, n (SD)</td>
<td>Sex Ethnicity (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s) BMJ Open
doi: 10.1136/bmjopen-2021-057885